Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;203(4):e98-e101.
doi: 10.1111/bjh.19022. Epub 2023 Aug 2.

Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax

Vincenzo Apolito  1   2 , Giulia Arrigo  3 , Loic Vasseur  4 , Matteo Olivi  1 , Silvia Perrone  3 , Valentina Giai  3 , Carolina Secreto  3 , Federica Di Biase  1 , Maria Carla De Simone  5 , Carolina Copia  5 , Angela Gravetti  5 , Roberto Freilone  3 , Benedetto Bruno  1 , Giuseppe Lanzarone  1 , Eloise Beggiato  1 , Chiara Frairia  3 , Ernesta Audisio  3 , Stefano D'Ardia  3 , Dario Ferrero  1 , Marco Cerrano  3 , Felicetto Ferrara  5
Affiliations

Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax

Vincenzo Apolito et al. Br J Haematol. 2023 Nov.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617-629.
    1. Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3:2911-2919.
    1. Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95:1511-1521.
    1. Candoni A, Lazzarotto D, Papayannidis C, Piccini M, Nadali G, Dargenio M, et al. Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with venetoclax. Am J Hematol. 2023;98:E80-E83.
    1. De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, et al. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience. Leuk Res. 2022;114:106803.

MeSH terms

LinkOut - more resources